Please assess the completion status of the following clinical trial:

Trial Title: Phase 1 Study of Trastuzumab Administered as a Single Intravenous Infusion

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* healthy adult subjects, age 18 to 55 years old~* able to understand procedures, agree to participate and willing to give informed consent~Exclusion Criteria:~* history of any significant disease~* use of any medication 7 days prior to start of study~* participation in a clinical trial within 30 days of start of study

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: t

Study Arms:
- Treatment A (Type: EXPERIMENTAL): Hercules: 8 mg/kg i.v. infusion over 90 minutes
- Treatment B (Type: ACTIVE_COMPARATOR): Herceptin EU: 8 mg/kg i.v. infusion over 90 minutes
- Treatment C (Type: ACTIVE_COMPARATOR): Herceptin US: 8 mg/kg i.v. infusion over 90 minutes

Based on this trial design, predict the completion outcome and termination type (if applicable).